FLFeng Liu

Feng Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Feng Liu has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Feng-Hou Gao

    Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201999, P.R. China

    5 shared publications
  • Hua Liu

    Tongji Univ, Hosp Affiliated 10, Dept Gastroenterol, Shanghai 200072, Peoples R China

    2 shared publications
  • Jia-Hui Guo

    Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oncol, 280 Mohe Rd, Shanghai 201900, Peoples R China

    2 shared publications
  • Jun‐Mei Yang

    Department of Clinical Laboratory Children's Hospital Affiliated to Zhengzhou University Zhengzhou China

    2 shared publications
  • Mei Zhao

    Department of Reproductive Medicine, Shanghai First Maternity and Infant Hospital Tongji University School of Medicine Shanghai China

    2 shared publications
  • Qiang‐Hua Yao

    Department of Pediatrics The First Affiliated Hospital of Zhengzhou University Zhengzhou China

    2 shared publications

Latest Publications

  • Open Access

    Therapeutic potential of tertiary lymphoid structures in breast cancer (Review)

    by Liangxiao Zhu, Meigui Li, Feng Liu, Fenghou Gao

    Tertiary lymphoid structures (TLS) are organized immune aggregates within the tumor microenvironment that are associated with improved prognosis and immunotherapy response in breast cancer, yet their functional duality and therapeutic potential require further clarification. The present review comprehensively summarizes current knowledge on TLS in breast cancer, focusing on their molecular mechanisms of formation and maturation, multifaceted functions in anti‑tumor immunity, established prognostic importance and emerging strategies for therapeutic targeting. The present study highlights that mature and functional TLS are key mediators of adaptive anti‑tumor immunity, whereas immature TLS may have opposing effects. Their presence and characteristics hold strong prognostic value and can predict response to immune checkpoint inhibitors. Consequently, therapeutic strategies aimed at inducing or enhancing TLS represent a promising direction for breast cancer immunotherapy. However, further research is needed to elucidate the precise regulatory networks and translate TLS‑focused strategies into clinical practice.


  • Open Access

    ZNF143-mediated upregulation of MEX3C promotes hepatocellular carcinoma progression

    by Lili Zhang, Nan Dang, Jiongyi Wang, Wenying Zhang, Xiaohua Hu, Bin Jiang, Dan Zhao, Feng Liu, Haihua Yuan


  • Open Access

    Tumor microenvironment immune-related lncRNA signature for patients with melanoma

    by Jia-Hui Guo, Shan-Shan Yin, Hua Liu, Feng Liu, Feng-Hou Gao

    Background: The incidence of malignant melanoma accounts for only approximately 5% of skin malignant tumors, however, it accounts for 75% of its mortality. Long-chain non-coding RNA (lncRNA) has a wide range of functional activities. Disorders of lncRNAs may lead to the occurrence and development of melanoma, and may also be related to immunotherapy. Methods: The transcriptomic data of primary and metastatic melanoma patients and 331 immune-related genes were downloaded from skin cutaneous melanoma (SKCM) in the The Cancer Genome Atlas (TCGA) database. On this basis, 460 immunologically relevant lncRNAs were identified by constructing a co-expression network of immunogenic genes and lncRNAs in primary and metastatic melanoma patients. Prognostic genes were screened using univariate Cox regression analysis. ROC analysis was performed to evaluate the robustness of the prognostic signature. Results: Univariate correlation analysis showed that only 3 of the 23 immune-related lncRNAs were at high risk and the rest were at low risk. Signatures of 7 immune-related lncRNAs were identified by multivariate correlation analysis. The clinical correlation analysis showed that the 7 immune-related lncRNAs were associated with the clinical stage of primary and metastatic melanoma. Principal component analysis (PCA) showed that only 7 immune-related lncRNA signals divided tumor patients into high-risk and low-risk groups, while the low-risk group was enriched in the immune system process M13664 and immune response M19817 sets. PPI interaction network analysis showed that 11 G protein-coupled receptors and 6 corresponding ligands in the 2 gene sets affected the tumor microenvironment and were negatively related to the risk of the 7 immune-related lncRNAs. The tumor microenvironment immune cell infiltration analysis also supported the finding that anti-tumor immunity in the low-risk group was stronger than in the high-risk group. Conclusions: These results indicate that characteristics of the 7 immune-related lncRNAs have prognostic value for melanoma patients and can be used as potential immunotherapy targets.


  • MicroRNA‐92b acts as an oncogene by targeting PTEN/AKT in NSCLC

    by Jia‐Hui Guo, Hai‐Yun Fang, Jun‐Mei Yang, Shan‐Ling Liu, Qiang‐Hua Yao, Yi‐Juan Fan, Mei Zhao, Feng Liu, Quan‐Wu Zhang, Feng‐Hou Gao

    MicroRNAs can act as tumour suppressors or oncogenes by regulating cellular differentiation, proliferation and apoptosis, and the dysregulation of miRNA is involved in the occurrence and development of NSCLC. Here, we provided evidence that miR‐92b as an oncogene in NSCLC by targeting PTEN/AKT. We found that miR‐92b was up‐regulated in human NSCLC tissues and cell lines. MiR‐92b knockdown suppressed the NSCLC cells proliferation and migration in both in vivo and in vitro models. Conversely, miR‐92b overexpression induced an aggressive phenotype. Moreover, miR‐92b‐mediated regulation of NSCLC cell proliferation and migration depended on binding to PTEN mRNA, which then led to the degradation of PTEN and activation of the downstream AKT signalling pathway. Overall, this study revealed the oncogenic roles of miR‐92b in NSCLC by targeting PTEN/AKT, and provided novel insights for future treatments of NSCLC patients.Significance of the study: MiR‐92b was up‐regulated in human NSCLC tissues and cell lines. Our study demonstrated that miR‐92b as an oncogene in NSCLC by targeting PTEN/AKT in both in vivo and in vitro models and provided novel insights for future treatments of NSCLC patients.


  • Open Access

    Oridonin induces Mdm2‐p60 to promote p53‐mediated apoptosis and cell cycle arrest in neuroblastoma

    by Han‐Qing Zhu, Chao Zhang, Zhu‐Ying Guo, Jun‐Mei Yang, Jia‐Hui Guo, Chen Chen, Qiang‐Hua Yao, Feng Liu, Quan‐Wu Zhang, Feng‐Hou Gao

    Oridonin could induce NB (neuroblastoma) cells growth inhibition by inducing apoptosis and cell cycle arrest, and the molecular mechanisms behind the effects deserve to be further explored. Here, oridonin was confirmed to cause the reactivation of p53 (cellular tumor antigen p53) to promote the expression of a series of apoptosis‐ and cell cycle arrest‐related proteins for the biological effects. During the process, oridonin relied on the caspase activation to cleave p53‐induced Mdm2 (E3 ubiquitin‐protein ligase Mdm2) to generate Mdm2‐p60. The generation of Mdm2‐p60 stabilized p53, and resulted in p53 accumulation for p53 continuous activation. In our research, it was also found that the reactivation of p53 induced by oridonin was closely related with the generation of ROS (reactive oxygen species). Taken together, these findings explain that oridonin exerts its anticancer activity partially by targeting the Mdm2‐p53 axis in NB cells, which lay an experimental base for future research of exploring the effects and molecular mechanisms of oridonin.


  • GSK3β-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells

    by Shan-Ling Liu, Zhen Liu, Li-Di Zhang, Han-Qing Zhu, Jia-Hui Guo, Mei Zhao, Ying-Li Wu, Feng Liu, Feng-Hou Gao

    Cyclin D1 and cyclin E1, as vital regulatory factors of G1-S phase cell cycle progression, are frequently constitutive expressed and associated with pathogenesis and tumorigenesis in most human cancers and they have been regarded as promising targets for cancer therapy. In this study, we established NVP-BEZ235, a potent dual kinase inhibitor, could induce neuroblastoma cells proliferation inhibition without apoptosis activation. Moreover, we showed NVP-BEZ235 could induce neuroblastoma cells arrested at G0/G1 phase accompanied with significant reduction of the cyclin D1 and E1 proteins in a dose dependent manner at nanomole concentration. Additionally we found that GSK3β was dephosphorylated and activated by NVP-BEZ235 and then triggered cyclin D1 and cyclin E1 degradation through ubiquitination proteasome pathway, based on the evidences that NVP-BEZ235 induced downregulation of cyclin D1 and cyclin E1 were obviously recovered by proteasome inhibitor and the blockade of GSK3β contributed to remarkable rescue of cyclin D1 and cyclin E1. Analogous results about its anti-proliferation effects and molecular mechanism were observed on neuroblastoma xenograft mouse model in vivo. Therefore, these results indicate that NVP-BEZ235-induced cyclin D1 and cyclin E1 degradation, which happened through activating GSK3β, and GSK3β-dependent down-regulation of cyclin D1 and cyclin E1 should be available for anticancer therapeutics.


  • Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival

    by YiMing Chen, Sandhya Gokavarapu, QingCheng Shen, Feng Liu, Wei Cao, YueHua Ling, Tong Ji


  • Open Access

    Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc

    by Feng-Hou Gao, Xiao-Hui Hu, Wei Li, Hua Liu, Yan-Jie Zhang, Zhu-Ying Guo, Mang-Hua Xu, Shi-Ting Wang, Bin Jiang, Feng Liu, et al.

    Background: Oridonin, a tetracycline diterpenoid compound, has the potential antitumor activities. Here, we evaluate the antitumor activity and action mechanisms of oridonin in colorectal cancer. Methods: Effects of oridonin on cell proliferation were determined by using a CCK-8 Kit. Cell cycle distribution was determined by flow cytometry. Apoptosis was examined by analyzing subdiploid population and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay. Senescent cells were determined by senescence-associated β-galactosidase activity analysis. Semi-quantitative RT-PCR was used to examine the changes of mRNA of p16, p21, p27 and c-myc. The concomitant changes of protein expression were analyzed with Western blot. Expression of AcH3 and AcH4 were examined by immunofluorescence staining and Western blots. Effects of oridonin on colony formation of SW1116 were examined by Soft Agar assay. The in vivo efficacy of oridonin was detected using a xenograft colorectal cancer model in nude mice. Results: Oridonin induced potent growth inhibition, cell cycle arrest, apoptosis, senescence and colony-forming inhibition in three colorectal cancer cell lines in a dose-dependent manner in vitro. Daily i.p. injection of oridonin (6.25, 12.5 or 25 mg/kg) for 28 days significantly inhibited the growth of SW1116 s.c. xenografts in BABL/C nude mice. With western blot and reverse transcription-PCR, we further showed that the antitumor activities of oridonin correlated with induction of histone (H3 and H4) hyperacetylation, activation of p21, p27 and p16, and suppression of c-myc expression. Conclusion: Oridonin possesses potent in vitro and in vivo anti-colorectal cancer activities that correlated with induction of histone hyperacetylation and regulation of pathways critical for maintaining growth inhibition and cell cycle arrest. Therefore, oridonin may represent a novel therapeutic option in colorectal cancer treatment.